-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
-
Summary
-
Supernus Pharmaceuticals, Inc. quarterly Deferred Income Tax Liabilities, Net history and growth rate from Q4 2019 to Q3 2024.
- Supernus Pharmaceuticals, Inc. Deferred Income Tax Liabilities, Net for the quarter ending September 30, 2024 was $7.36M, a 79.1% decline year-over-year.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Deferred Income Tax Liabilities, Net, YoY Quarterly Growth (%)